

Antisense & RNAi Therapeutics Market Size Expected To Reach \$2 Billion By 2027

*The Business Research Company's
Antisense & RNAi Therapeutics Global
Market Report 2023 – Market Size,
Trends, And Global Forecast 2023-2032*

LONDON, GREATER LONDON, UK,
March 15, 2023 /EINPresswire.com/ --
The Business Research Company's
global market reports are now updated
with the latest market sizing
information for the year 2023 and
forecasted to 2032

The logo for The Business Research Company, featuring the company name in a serif font and a stylized bar chart with three bars of increasing height to the right.

The Business
Research Company

Antisense & RNAi Therapeutics Global Market Report
2023 : Market Size, Trends, And Global Forecast 2023-
2032

The Business Research Company's "Antisense & RNAi Therapeutics Global Market Report 2023" is a comprehensive source of information that covers every facet of the antisense & RNAi therapeutics market. As per TBRC's [antisense & RNAi therapeutics market forecast](#), the antisense & RNAi therapeutics market is expected to grow from \$2.42 billion in 2027 at a CAGR of 12.0%.

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. North America is expected to hold the largest antisense & RNAi therapeutics market share. Major players in the antisense & RNAi therapeutics market include Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline PLC., Ionis Pharmaceuticals.

Learn More On The Antisense & RNAi Therapeutics Market By Requesting A Free Sample
(Includes Graphs And Tables):

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp>

Trending Antisense & RNAi Therapeutics Market Trend

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as with academic and research institutions in this market by way of partnerships, and in or

out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a \$2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive \$150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam's cardiometabolic disease programs. In 2020, Aro Biotherapeutics Company has announced a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the market leader in RNA-targeted therapeutics, under which Ionis will use Aro's CENTYRINTM technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs).

Antisense & RNAi Therapeutics Market Segments

- By Technology: RNA Interference, Antisense RNA
- By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
- By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
- By Geography: The global antisense & RNAi therapeutics market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read more on the global antisense & RNAi therapeutics market report at:

<https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report>

Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs.

Antisense & RNAi Therapeutics Global Market Report 2023 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Antisense & RNAi Therapeutics Global Market Report 2023 by The Business Research

Company is the most comprehensive report that provides insights on antisense & RNAi therapeutics global market size, drivers and trends, antisense & RNAi therapeutics global market major players, competitors' revenues, market positioning, and antisense & RNAi therapeutics global market growth across geographies. The antisense & RNAi therapeutics global market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:
Neurodegenerative Disorder Therapeutics Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report>

Alzheimer's Disease Treatment Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report>

Digital Therapeutics Global Market Report 2023

<https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 3000+ detailed industry reports, spanning over 3000+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Blog: <https://blog.tbrc.info/>

Healthcare Blog: <https://healthcareresearchreports.com/>

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/622272926>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.